KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short term Debt: 2011-2019

Historic Short term Debt for Nektar Therapeutics (NKTR) over the last 2 years, with Dec 2019 value amounting to $252.9 million.

  • Nektar Therapeutics' Short term Debt was N/A to $254.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $254.1 million, marking a year-over-year change of. This contributed to the annual value of $252.9 million for FY2019, which is N/A change from last year.
  • Per Nektar Therapeutics' latest filing, its Short term Debt stood at $252.9 million for FY2019, which was up 17.65% from $215.0 million recorded in FY2011.
  • In the past 5 years, Nektar Therapeutics' Short term Debt registered a high of $252.9 million during FY2019, and its lowest value of $252.9 million during FY2019.
  • In the last 1 years, Nektar Therapeutics' Short term Debt had a median value of $252.9 million in 2019 and averaged $252.9 million.